Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
American Journal of Clinical Pathology
|
March 18, 2011
Common genomic aberrations in basaloid squamous cell carcinoma and carcinosarcoma of the esophagus detected by CGH and array CGH
Inga-Marie Schaefer, Christina Enders, Andreas Polten, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2016
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Mikael Eriksson, Peter Reichardt, Kirsten Sundby Hall, et al.
American Journal of Clinical Pathology
|
December 29, 2016
Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors
Larissa Merten, Abbas Agaimy, Evgeny A Moskalev, et al.
Radiation and Environmental Biophysics
|
April 19, 2013
Rat model of fractionated (2 Gy/day) 60 Gy irradiation of the liver: long-term effects
Margret Rave-Fränk, Ihtzaz Ahmed Malik, Hans Christiansen, et al.
International Journal of Cancer
|
July 27, 2017
The expression of hematopoietic progenitor cell antigen CD34 is regulated by DNA methylation in a site-dependent manner in gastrointestinal stromal tumours
Irina Bure, Alexander Braun, Claudia Kayser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
Heikki Joensuu, Eva Wardelmann, Mikael Eriksson, et al.
British Journal of Cancer
|
June 11, 2024
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
Heikki Joensuu, Annette Reichardt, Mikael Eriksson, et al.
JAMA Oncology
|
March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial
Heikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
JAMA Oncology
|
May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
International Journal of Cancer
|
July 22, 2014
Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of SPP1 as an independent prognostic factor
Florian Haller, Jitao David Zhang, Evgeny A Moskalev, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
American Journal of Clinical Pathology
|
March 18, 2011
Common genomic aberrations in basaloid squamous cell carcinoma and carcinosarcoma of the esophagus detected by CGH and array CGH
Inga-Marie Schaefer, Christina Enders, Andreas Polten, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2016
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Mikael Eriksson, Peter Reichardt, Kirsten Sundby Hall, et al.
American Journal of Clinical Pathology
|
December 29, 2016
Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors
Larissa Merten, Abbas Agaimy, Evgeny A Moskalev, et al.
Radiation and Environmental Biophysics
|
April 19, 2013
Rat model of fractionated (2 Gy/day) 60 Gy irradiation of the liver: long-term effects
Margret Rave-Fränk, Ihtzaz Ahmed Malik, Hans Christiansen, et al.
International Journal of Cancer
|
July 27, 2017
The expression of hematopoietic progenitor cell antigen CD34 is regulated by DNA methylation in a site-dependent manner in gastrointestinal stromal tumours
Irina Bure, Alexander Braun, Claudia Kayser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
Heikki Joensuu, Eva Wardelmann, Mikael Eriksson, et al.
British Journal of Cancer
|
June 11, 2024
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
Heikki Joensuu, Annette Reichardt, Mikael Eriksson, et al.
JAMA Oncology
|
March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial
Heikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
JAMA Oncology
|
May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
International Journal of Cancer
|
July 22, 2014
Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of SPP1 as an independent prognostic factor
Florian Haller, Jitao David Zhang, Evgeny A Moskalev, et al.
Page
of 7